title: Intermediate-risk childhood acute lymphoblastic leukemias: amsacrine + cytosine arabinoside versus intermediate-dose methotrexate for consolidation, and 6-mercaptopurine + methotrexate + vincristine versus monthly pulses for maintenance.
authors.forename: G
authors.initials: G
authors.lastname: Schaison
authors.forename: G
authors.initials: G
authors.lastname: Leverger
authors.forename: A
authors.initials: A
authors.lastname: Bancillon
authors.forename: M
authors.initials: M
authors.lastname: Marty
authors.forename: D
authors.initials: D
authors.lastname: Olive
authors.forename: G
authors.initials: G
authors.lastname: Cornu
authors.forename: C
authors.initials: C
authors.lastname: Griscelli
authors.forename: S
authors.initials: S
authors.lastname: Lemerle
authors.forename: J L
authors.initials: JL
authors.lastname: Harousseau
authors.forename: M
authors.initials: M
authors.lastname: Bonnet
mesh_terms: D000677:Amsacrine / Q000008:administration & dosage; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D002648:Child; D002986:Clinical Trials as Topic; D003561:Cytarabine / Q000008:administration & dosage; D004334:Drug Administration Schedule; D006801:Humans; D007945:Leukemia, Lymphoid / Q000188:drug therapy*; D015122:Mercaptopurine / Q000008:administration & dosage; D008727:Methotrexate / Q000008:administration & dosage; D011897:Random Allocation; D012306:Risk; D014750:Vincristine / Q000008:administration & dosage
chemical_list: D000677:Amsacrine; D003561:Cytarabine; D014750:Vincristine; D015122:Mercaptopurine; D008727:Methotrexate